Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kanuma

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

National Institute for Health and Care Excellence NICE logo

Another NICE no for AZ’s new ovarian cancer drug

Cost watchdog wants more information for Lynparza

- PMLiVE

AstraZeneca expands antisense alliance with Isis

Builds on existing deal that sees the firm develop new medicines for a host of diseases

AstraZeneca AZ

Setback for AZ’s MEK inhibitor selumetinib

Drug fails at phase III in uveal melanoma

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

- PMLiVE

AstraZeneca forms ‘smart inhaler’ digital health partnership

Follows separate deal for a health coaching app for heart attack patients

- PMLiVE

The Partners appoints new creative director

Award-winning Peter Henshaw joins from InVentive Europe

AstraZeneca AZ

Iressa set for US market return after FDA approval

AstraZeneca'slung cancer drug wins green light for EGFR tumours

- PMLiVE

AstraZeneca’s Amie Baker wins Communiquétor 2015 award

And the UK pharma company takes home In-House team of the Year

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Executive leak continues at AZ as another head jumps ship

James Ward-Lilley will become CEO of lung drug specialist Vectura

- PMLiVE

AstraZeneca and its diabetes plans

Director of marketing Chris Boulton is bullish on its prospects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links